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Executive summary
Information on the human toxicokinetics, or biological fate of a substance, plays an important role in human safety assessment. While there are few explicit requirements in EU chemicals legislation for the generation of human toxicokinetic data, such as human in vitro or in vivo measurements or computational predictions, the use of these data to support the assessment of systemic toxicity is widely recommended in regulatory guidance. For the generation of data, some EU test methods and OECD test guidelines are available, but these are mostly based on animal procedures, the traditional means of obtaining whole-body toxicokinetic parameters. Exploiting modern developments in predictive toxicology, there are increasing opportunities to generate human wholebody toxicokinetic information by using physiologically-based toxicokinetic (PBTK) models. These models provide a means of integrating human data generated by in silico and in vitro methods for absorption, distribution, metabolism and excretion (ADME), the four underlying processes driving toxicokinetic behaviour. In general however, the lack of standardisation of these methods is hampering their regulatory acceptance and use.
This report outlines the strategy proposed by the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) for achieving a 3Rs (replacement, reduction and refinement of animal experiments) impact in the area of toxicokinetics. The EURL ECVAM strategy identifies opportunities for generating and making better use of toxicokinetic data. Apart from specifying strategic aims and associated objectives to progress this field, the strategy is also intended to provide a framework for the identification and prioritisation of alternative test methods for ADME.
Efforts in this area should be directed towards developing standards that will increase the development, harmonisation, validation and acceptance of human-relevant methods for ADME of substances, including nanomaterials. This will enable the generation of reliable data for toxicokinetic modelling in support of chemical safety assessment. Although ADME and toxicokinetics usually consider single substances, the information obtained may inform on risk assessment issues of mixtures and combined exposures as well. In parallel, in order to promote modelling efforts, an infrastructure needs to be established to make any human data, as well as existing animal data, readily available. To enhance the uptake of PBTK models, good modelling practice needs to be further developed and accepted at an international level. Finally, guidance is needed on how best to use human ADME and toxicokinetics data for decision making purposes. Regulatory anchoring might provide a boost in this respect. These efforts are expected to lay the foundation for a risk assessment approach that is increasingly based on human data, ultimately obviating the need for animal studies.
The implementation of this strategy will rely not only on the efforts of EURL ECVAM, but on the collective and coordinated contribution of a wide range of stakeholders. 
Glossary

-Introduction
Toxicokinetics (TK) describes the concentration and time-dependent fate of a substance within an organism whereas toxicodynamics describes the subsequent interaction with biological targets and how this may lead to adverse health effects. The time-course of the internal or systemic exposure is the combined outcome of four underlying processes: absorption, distribution, metabolism and excretion (ADME). Although they are strongly linked, it is important to distinguish between ADME and TK. In vitro methods can provide data on individual ADME parameters, but do not directly generate whole-body (animal or human) TK parameters such as the maximum concentration reached in blood/plasma. Traditionally, TK parameters have been obtained from in vivo experiments, but there are increasing opportunities to derive this information by physiologicallybased toxicokinetic (PBTK) modelling (Figure 1 ). PBTK models provide a means of simulating TK profiles by integrating (chemical-independent) physiological and anatomical information with (chemical-dependent) ADME parameters. The latter can be generated by quantitative structureactivity relationship (QSAR) models and in vitro methods. PBTK models are increasingly being used in the chemical risk assessment process to take into account relevant in vivo differences (crossspecies, cross-route and inter-individual) and to make better use of in vitro toxicity results. There are very few legal requirements in the EU chemicals legislation for the generation of human ADME and TK data and the requirements for ADME and TK data are not consistent (Table 1) . However, the use of ADME/TK data when available to support the assessment of systemic toxicity is highly recommended in regulatory guidance and scientific opinions (Table 2 ). For the generation of new data, only three ADME/TK test methods are available in the EU test methods regulation (EU, 2012) and in the OECD (Organisation for Economic Co-operation and Development) guidelines for the testing of chemicals. With the exception of OECD TG 428 for in vitro dermal absorption, guideline methods such as OECD TGs 417 and 427 are based on animal tests (OECD, 2004a; OECD, 2004b; OECD, 2010) . OECD TG 417 studies typically provide rather isolated species-, dose-, and route-specific (mostly oral) data on absorption, tissue distribution or metabolism. In rare cases, OECD TG 417 is used to give the integrated TK profile of a substance, i.e. the concentration-time course of the parent compound and its metabolites. Although many in silico and in vitro methods with varying stages of maturity are available and used for integrated PBTK modelling to predict the concentration-time course, these methods are not generally sufficiently standardised (Bessems et al., 2014) and scrutinised for relevance and reliability which is hampering their regulatory acceptance and widespread use.
The need for human TK information on one hand, combined with the paucity of legal requirements for animal TK data on the other, provides an opportunity to develop a risk assessment approach that is increasingly based on human ADME and TK data. A fundamental transition is needed in the toxicological testing and risk assessment methodology away from the widely used default approach using external animal dose levels and external human exposures. At best this only accommodates the use of species-and route-specific information on absorption, instead of taking the systemic exposure (AUC, Cmax etc.) into account. A scientifically more advanced and toxicologically relevant approach based on internal concentrations is highly recommended. In addition to regulatory drivers (e.g. EU ban on animal testing of cosmetic ingredients), such a transition is motivated by scientific considerations. Animals are often poor models for humans due to sometimes well-known qualitative and also quantitative differences in their physiology and metabolism (Coecke et al., 2005; Pelkonen et al., 2009; Greek and Menache, 2013; Coecke et al, 2014) . In order to use human in vitro toxicity data for human risk assessment, a stronger focus on internal exposure (e.g. AUC and Cmax of the putative toxicant) is warranted. In this approach, in vitro free (unbound to protein) concentrations (points of departure) would be compared to simulated or measured (e.g. by biomonitoring) human in vivo systemic exposure free concentrations. The resulting margin of internal exposure would then be used to characterise the risk (Bessems et al., manuscript in preparation) .
Until a full replacement of animal testing for systemic toxicity is reached, a more intelligent and systematic generation and use of ADME/TK information will provide a means of reduction and refinement. For example, the reliable prediction of extremely low absorption could support the waiving of animal toxicity test requirements based on the low internal exposure expected. The prediction and the measuring of internal exposure can also support dose range finding, e.g. avoiding irrelevant high-dose testing if high doses are predicted to result in kinetic non-linearity. Measuring systemic exposure across dose levels, sexes, study durations, species, strains and life stages in ongoing animal toxicity studies, i.e. without using satellite animals (preferably using microsampling), will significantly reduce uncertainties involved in various extrapolations needed in the risk characterisation phase (Bessems and Geraets, 2013; Terry et al., 2014) . Moreover, it may reduce the chance that the results of one animal study will unnecessarily trigger another. This could happen for example when non-linearity of the dose-response is caused by non-linearity of the internal exposure. Lastly, ADME properties form an important source of information in integrated approaches to testing and assessment (IATA) that are designed to optimally exploit various streams of non-animal data (OECD, 2015) .
The purpose of this document is to present the EURL ECVAM strategy to avoid, reduce and refine animal testing in the assessment of toxicokinetics and systemic toxicity of substances. This strategy is also applicable to nanomaterials, although specific technical provisions are needed in places due to their particular physicochemical properties. The intention was to focus on pragmatic options that could be expected to have a significant short to mid-term 3Rs impact, while at the same time laying the foundation for a risk assessment approach that is increasingly based on human ADME/TK data. The implementation of this strategy will rely not only on the efforts of EURL ECVAM, but on the collective and coordinated contribution of a wide range of stakeholders.
-Regulatory provisions on ADME and TK
Within EU regulatory frameworks, route-to-route extrapolation is probably the most important usecase for information on species-and route-specific ADME and, if available, systemic exposure (whole-body TK). However, such information is not consistently required. Table 1 provides an overview of data requirements and recommendations under the frameworks that are most relevant in this respect, i.e. CLP (classification and labelling), REACH (industrial chemicals), CPR (cosmetics), BPR (biocides) and PPPR (pesticides). It is noted that over time, legislative frameworks have placed increasing emphasis on the use of systemic exposure information for human risk assessment purposes. Except for the CPR however, these needs are being addressed for the most part using animal data. Table 2 provides examples of how the required and/or recommended ADME/TK information can be used in regulatory decision making in the EU. IATA ADME and TK models are regarded to be basic elements.
ECHA report alternatives (ECHA, 2014), OECD WS Report (OECD, 2015) Skin bioavailability critical event in adverse outcome pathway skin sensitisation.
EURL ECVAM Strategy Skin sensitisation (Casati, 2013) Metabolic stability/clearance + metabolite identification in vitro. Possibly preventing in vivo acute systemic tox. testing.
EURL ECVAM Strategy Acute systemic toxicity (Prieto, 2014) In vivo study design 
Risk management
Persistency and bioaccumulation noted as selection criterion for the emerging chemical risk framework.
EFSA (2014),
EURL ECVAM Strategy fish acute toxicity + bioaccumulation (Halder, 2014) Establishment of 'common assessment groups' using human metabolism (in silico, in vitro, in vivo) in public health issue of exposure to mixtures.
EFSA, 2014
4 Waiving an information need (animal study): based on arguments, not deemed necessary to carry out the study. Comparisons between human and animal ADME/TK data (in silico, in vitro or preferably in vivo when available) can lead to an overall reduction of animal testing by increasing the relevance of animal toxicity studies, where these are required. This is achieved by identifying and avoiding animal species with ADME/TK for the substance that is very different from human ADME/TK. This could be based on comparison of any relevant parameter or process, e.g. most relevant metabolite(s), rate of formation of a likely toxic metabolite, and allometric scalability of various kinetic parameters such as hepatic metabolic clearance, renal clearance or plasma half-life (Bessems and Geraets, 2013) . In addition, risk assessment is served best when more human ADME/TK data is available. The EFSA PPR panel noted for example already in 2006 that human ADME/TK data reduce the uncertainty related to the extrapolation process from animal toxicodynamics data both in terms of species and dose, and help in assessing the relevance for humans of findings in animals (EFSA, 2006).
There are international developments as well. OECD Guidance Document 116 on chronic and carcinogenicity test guidelines (OECD, 2012) attributes significant value to information on ADME for improving the study design. The information helps to select the highest relevant dose level in order to prevent non-linear kinetics from occurring, thus enabling refinement through study design. OECD Guidance Document 151 supports the extended one generation reproductive toxicity test guideline (OECD, 2013) . It states that "ADME studies should be undertaken to facilitate extrapolation from the oral to the dermal route, if this is required". Furthermore, ADME received attention at a recent OECD workshop as being an important element of IATA (OECD, 2015) .
-Strategy to replace, reduce and refine the use of animals for human TK
Although the value of human ADME and TK data in establishing health risks of substances is widely acknowledged, concrete guidance and case studies on how to generate the in vitro ADME and in silico TK parameters and how to use this information in different decision making contexts and within IATA is largely missing. Some human in vitro methods to measure an ADME property exist, such as for absorption via the gastrointestinal tract or for hepatic metabolic clearance, albeit with uncertainties regarding their applicability domain. In other cases, such as renal excretion, further efforts are needed to develop suitable methods (Mostrag-Szlichtyng and Worth, 2010; Adler et al., 2011; Bessems et al., 2014; EFSA, 2014) . In most cases however, the available methods are not standardised. This is an impediment to their use and acceptance. Therefore, in addition to the development of new methods, there is a need to characterise existing methods in a systematic manner (Adler et al., 2011; Bessems et al., 2014; EFSA, 2014) .
With a view to replacing, reducing and refining animal testing in the assessment of toxicokinetics and systemic toxicity, EURL ECVAM has defined four strategic aims (Figure 2 ).
ADME methods:
Development and standardisation of human in vitro ADME methods.
Kinetic modelling:
Portals and good kinetic modelling practice.
Data collection:
Analytics and databases to serve kinetic modelling.
Regulatory anchoring:
Legislation and guidance on human ADME/TK data.
The first three are intended to enhance the availability and usefulness of the necessary tools while the fourth is intended to foster a regulatory evolution towards stronger requirements for ADME and TK information based on non-animal and human-relevant approaches. In the following paragraphs, the four strategic aims are further explained and translated into concrete objectives. 
Strategic aim 1: Development and standardisation of human ADME methods
In order to promote the acceptance of non-animal ADME/TK data for regulatory purposes, an international quality assurance framework needs to be established (SCHER, 2013; Coecke et al. 2014) . This framework should be applicable to ADME data generated by in vitro test methods and QSARs, TK data generated by integrated PBTK models, as well as human in vivo data obtained in monitoring programs or volunteer studies (SCHER, 2013).
Some elements of this framework are already established or under development. For example, the QSAR Model Reporting Format (QMRF) and QSAR Prediction Reporting Format (QPRF) are internationally recognised standards for reporting the characteristics of QSAR models, and the quality of QSAR predictions, respectively 6 . More recently, the OECD has published a guidance document on how to characterise and describe non-guideline in vitro test methods . Guidance on the characterisation, documentation and application of PBTK models has been published by the World Health Organisation (WHO/IPCS, 2010).
Other elements of this framework need to be developed. In particular, standards for in vitro ADME methods will provide a means of characterising and comparing in vitro methods which typically provide the same kind of information (ADME property) but which may differ considerably in terms of the underlying test systems and experimental protocols used. Different domains (varying physicochemical properties, magnitude of output parameter) may require different standards.
Lastly and as mentioned earlier, for several ADME endpoints, test methods need to be developed, improved or their applicability domain widened.
Objective 1.1 -Development of standards for human in vitro ADME methods
In order to make better use of human in vitro methods for ADME properties, there is a need to develop a framework aiming to (a) describe a method including the characteristics of the test system and the results of the test method in an objective and standardised way, (b) to assess the performance of the method (reliability and relevance) and (c) to define its applicability in terms of the ranges of physicochemical properties of substances, its measurement outputs and the timescales for which the test system is valid.
Furthermore, the OECD reporting standard for non-guideline in vitro methods (OECD, 2014) needs to be evaluated for its applicability to ADME methods. Additional standards may need to be established to characterise and compare different methods within a given class of methods (that generate the same ADME parameter). A few other important issues need to be taken into consideration here. One issue is the fact that not all ADME methods are necessarily designed to be directly predictive of an in vivo parameter as such. This means that the classical validation based on a direct comparison of a human in vitro ADME method data against human in vivo data is not meaningful 7 . Prediction methods as complex as PBTK models would be needed to interpret the human in vitro ADME data. Nevertheless, simple ADME parameters obtained using standardised 6 JRC QSAR Model Database and QSAR Model Reporting Formats. https://eurl-ecvam.jrc.ec.europa.eu/databases/jrc-qsarmodel-database-and-qsar-model-reporting-formats. 7 In this context, this could mean total in vivo absorption (relative to the applied dose) measured over 7 days. Whereas an in vitro absorption method may deliver a flux, being an absorption rate per unit area (e.g. μmol min -1 cm 2 ).
human in vitro methods could be used directly such as for priority setting and ranking (rates of absorption) as well as in the context of IATA.
Objective 1.2 -Human route-specific absorption methodology
For in vitro dermal absorption, an OECD TG does exist (TG 428). However, this TG needs critical review and/or revision as the current method is focussed mainly on determining the relative amount of substance systemically absorbed and much less so on establishing dermal flux values (through the skin) and the underlying determinants such as dermal diffusion coefficients that may be needed for PBTK modelling (Bessems et al., 2014) . EFSA has published opinions on the adaptation and improvement of this TG, especially in relation to the interpretation and standardised reporting of results of OECD TG 428 (EFSA, 2011; EFSA, 2012) . For other routes, OECD TGs and validated test methods are lacking.
It is important to improve and/or standardise a set of representative in vitro methods that can be used to derive harmonised standards for this class of test methods (which measure the permeability of external membranes). This is relevant to methods for assessing exposure via skin as well as by inhalation or ingestion. Although this formally applies to tissue distribution, a further step will be to improve and develop equivalent test methods and standards for in vitro methods that measure the passive permeability of internal membranes, such as the blood-brain barrier and the placental barrier. Obviously, in the end the same applies to active transport across barriers.
Objective 1.3 -Human tissue distribution and protein binding methodology
Several in vitro test methods that measure parameters that drive the distribution (partitioning coefficients, protein binding), including an indication of their level of development, are described elsewhere (Bessems et al., 2014) . Distribution is a key driver of phenomena like persistency. For example, high fat solubility increases the risk of persistency and bioaccumulation.
A set of standards to improve the quality and traceability of PBTK input parameters such as partitioning coefficients and protein binding is crucial. Improvements and widening of applicability domains may be needed as well.
Objective 1.4 -Human metabolic stability/clearance methodology
Human metabolic clearance levels (or their absence, defined as metabolic stability) in liver, skin and lungs being the most relevant portals of entry, are important determinants of bioavailability as well as the (pre-systemic) elimination of substances from the body. These are essential pieces of information for PBTK modelling. Metabolic clearance might even be the most influential parameter that determines terminal elimination half-life (and thus persistency and risk for human bioaccumulation), systemic toxicity upon dermal exposure, as well as inter-individual variability in plasma levels. Harmonised standards are needed since the methods submitted to EURL ECVAM and available in the scientific literature vary considerably. For example, there are differences in the in vitro test system (e.g. subcellular fraction, primary cells, cell lines, liver slices) and the ability to deal with fast or slowly cleared compounds (Brandon et al., 2003; Di and Obach, 2015) .
Objective 1.5 -Human xenobiotic metabolic pathway profiling methodology
The identification of the main and most relevant human metabolites serves multiple applications. For example, the identification of common metabolites for two substances in a mixture might trigger the assessment to be based on the properties of the common active metabolite. As a multitude of methods is used under various performance requirements, a set of standards needs to be developed for this class of methods. Induction and inhibition of biotransformation enzymes are important process as well. Induction is currently the subject of a draft OECD TG.
Objective 1.6 -Human route-specific excretion methodology
Urinary and biliary excretion pathways are the two most relevant excretion pathways. To our knowledge, there are no in vitro methods available at the moment for urinary excretion because of the complex renal mechanism of formation of primary urine, passive and active reuptake and the dependence of these mechanisms on differences in pressure and osmolarity between blood and primary urine. For biliary clearance, some in vitro methods have been reported (De Bruyn et al., 2013) , but further development and standardisation work is necessary to identify representative methods based on which harmonised standards can be established. Although passive excretion has been suggested to suffice for 'Tier 1 PBTK modelling', it is clear that in the future, excretion based on active transporters needs to be taken into account as well.
Strategic aim 2: Kinetic modelling
In order to facilitate the use of PBTK modelling in the risk assessment process, there is a need to make in silico ADME prediction tools as well as PBTK modelling tools readily accessible and easy to apply, and to establish good practice in kinetic modelling (WHO/IPCS, 2010).
Objective 2.1 -Comprehensive web-based kinetic modelling portals
Kinetic modelling includes classical kinetic modelling approaches, PBTK modelling, and also in silico prediction of ADME parameters. It is generally felt to be quite a complex process that requires experts in TK, mathematical modellers and regulatory risk assessors to work together (WHO/IPCS, 2010; Bessems et al., 2014) . The establishment of comprehensive 'one-stop' web-based kinetic modelling portals is needed to provide a collaborative environment to facilitate the development and use of kinetic models. Such portals should contain or link to freely available kinetic modelling tools and databases (objective 3.2).
Objective 2.2 -Good kinetic modelling practice
To facilitate the regulatory acceptance of PBTK models, good practice needs to be established for the development and documentation of models based on already available guidance (WHO/IPCS, 2010) . It is necessary to develop standard reporting formats, equivalent in purpose to the QSAR Model Reporting Format (QMRF) and QSAR Prediction Reporting Format (QPRF), for presenting sufficient details of model construct and application. These reporting formats should include assumptions made concerning the mode of action, the most relevant qualitative dose metric (parent or metabolite), the most relevant quantitative dose metric (AUC, Cmax, rate of formation) and address uncertainty issues (see also 3.4). This will help kinetic model developers to take into account all the necessary considerations and facilitate uptake of kinetic modelling approaches in decision making.
The formation of a PBTK modelling expert group, ideally by an international organisation, would be an appropriate means of developing good PBTK modelling practice.
Strategic aim 3: Data collection -Generation and storage of ADME and TK data
To support objectives 1 and 2, a concerted action to stimulate generation and collection of data is needed. These data should ideally be quality-assured and stored in readily accessible (and preferably free-to-use) databases in order to make the process of establishing human ADME and TK parameters as transparent and efficient as possible (Bessems et al., 2014) . Sharing of proprietary data could enable the generation of a large, high quality database of 'paired' in vitro and in vivo human data on the same substance. This could be used to investigate the predictive value of in vitro data (Leist et al., 2014) . Databases are a necessary building block for ready to use PBTK modelling and should become an important part of comprehensive web-based PBTK modelling platforms (see objective 2.1).
Objective 3.1 -Collection of human in vitro ADME and in vivo TK information
There is considerable need for standardised in vitro generation of ADME parameters. Ideally, these ADME parameters should be stored in open-access curated databases. This would speed up the development of in silico (QSAR) ADME prediction tools as well as the parameterisation of PBTK models.
Simultaneous measurements of external exposure and systemic exposure in order to establish reallife human TK are scarce. A concerted effort is necessary to collect and store in vivo human ADME and TK information by building on human exposure monitoring programmes (e.g. dietary intake studies, occupational monitoring) as well as on human biomonitoring programmes (e.g. measurements in biofluids). If doubts remain and more specific human in vivo benchmarking is required, controlled human microdosing in volunteer studies could be performed with the use of specific isotope labelling (Madeen et al., 2015) .
Objective 3.2 -Databases
In order to facilitate human PBTK modelling, centralised publicly available (web-based) databases facilities containing the following are crucial:
 A collection of human ADME data obtained by in vitro measurements.  Anatomical and physiological data including their variation in the human population. An example is the RIVM Interspecies database (http://www.interspeciesinfo.com);  In vivo human TK information. An example is the EURL ECVAM KinParDB (https://eurlecvam.jrc.ec.europa.eu/validation-regulatory-acceptance/toxicokinetics).
Sparse but relevant kinetic data may already be available in various databases from the JRC and others that were not specifically designed for storage of ADME data, such as DB-ALM, the DataBaseservice on ALternative Methods (http://ecvam-dbalm.jrc.ec.europa.eu), the QSAR Model Database (http://ihcp.jrc.ec.europa.eu/our_databases/jrc-qsar-inventory) and databases that participate in the OECD eChemPortal (http://www.echemportal.org/echemportal/propertysearch/page.action?pageID=0).
Objective 3.3 -Sampling strategies, methods, preparations and analytical determination
Sampling strategies, sampling methods, sample pre-treatment and final analytical determination and quantification are all necessary for the transition to a human-based IATA. This pertains to in vitro ADME testing (Broeders et al., 2012) and to the collection of human in vivo data on TK (biomonitoring and human volunteer studies). This also concerns in vitro toxicity testing where the in vitro kinetics should be measured, i.e. the concentration-time profile of the chemical and/or metabolites intracellular as well as in the incubation medium (Blaauboer, 2010; Wilmes et al., 2013) . And it pertains as well to animal toxicity testing as long as it is still performed in order to improve study design and value for risk assessment (Creton et al., 2012) . The issue was identified previously as a high priority (Bessems et al., 2014) , i.e. 'high-throughput and low cost analytical facilities to measure chemicals in physiological media'.
Strategic aim 4: Regulatory anchoring of human ADME and TK
The inherent value of human ADME and TK information in risk assessment is obvious, be it based on in silico, in vitro and/or in vivo approaches. However, it is not always obvious which particular ADME parameter (e.g. relative absorption or absorption rate), or which TK parameter (e.g. AUC or Cmax) is needed for a particular decision. Clarity is often lacking too regarding if and how human variability should be taken into consideration and what level of uncertainty is tolerable for various ADME/TK information elements.
Objective 4.1 -Guidance on the use of human ADME and TK data in IATA
Reliable information on human ADME parameter values is helpful in the development and application of IATA. For example, extremely low absorption rates could justify the waiving of certain animal bioassays (analytical precision becomes very important here, see objective 3.3), local (skin) bioavailability is a key consideration for assessing skin sensitisation, and low whole body clearance, indicated by low urinary excretion and/or high metabolic stability, indicates human persistency of a substance. Further guidance is therefore needed on the use of ADME/TK data in IATA for specific endpoints, including how to characterise the uncertainty in conclusions drawn from these data. Uncertainty may result, for example, from the reliability and relevance of the underlying ADME/TK methods.
Objective 4.2 -Evolution of legislative anchoring of human ADME and TK information
There is growing awareness that human-relevant ADME and TK data are instrumental for a much stronger role of non-animal approaches in regulatory risk assessment. This implies a transition from the current animal-based testing paradigm to one that is based on 21 st century science with greater reliance on human-relevant in vitro testing and human in vivo data (US NAS, 2007; SCHER, 2013; US EPA, 2014) . In order to achieve this, there is a need for a stronger regulatory anchoring of human in silico and in vitro ADME data, of human PBTK modelling tools to integrate human ADME data as well as of collecting human in vivo data where possible to support this.
Timelines
In Figure 3 , an overview is presented of the strategic aims and related objectives with indicative timelines for meeting the objectives. This assumes optimal conditions in terms of the availability of necessary expertise and resources. 
-Conclusions
This document presents EURL ECVAM's strategic view on how to achieve a significant 3Rs impact in the assessment of toxicokinetics and systemic toxicity. Grouped under four strategic aims, a number of objectives and related activities have been identified to foster the generation and more intelligent use of human toxicokinetic data. In particular, the development of standards and a quality assurance framework to support the acceptance of human ADME/TK methods, and the targeted generation of relevant in silico and in vitro toxicokinetic data and their integration via PBTK modelling is expected to have a significant impact on the 3Rs. These activities will also lay the foundation for a more human-relevant approach to the safety assessment of chemicals. This strategy document is also intended to provide a framework for the prioritisation of alternative test methods for validation by EURL ECVAM towards regulatory acceptance and use.
EURL ECVAM has already taken some important steps consistent with these strategic aims. For example, a pilot project delivered a kinetic parameters database (KinParDB) as well as a userfriendly kinetic modelling tool (KinCalTool). More recently, EURL ECVAM has started to explore the development of standards for human in vitro hepatic metabolic clearance methods. Furthermore, with a view to developing a risk assessment approach based entirely on non-animal methods, EURL ECVAM has been working closely with other partners within the SEURAT-1 initiative to explore the use of in silico models in performing route-to-route extrapolations and in vitro-to-in vivo comparisons.
The strategy outlined here is intended to be inclusive. EURL ECVAM has an important role to play in its implementation, but achievement of the objectives will depend on the proactive and coordinated engagement of multiple stakeholders. EURL ECVAM will continue to review its work programme in the light of developments in this field and with a view to providing added value at the EU and international levels.
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